Indy’s top 11 acquisition deals, before Anthem-Cigna
Anthem’s $54 billion bid for rival insurer Cigna is twice the size of the next-largest acquisition in the Indianapolis area, which occurred nearly a decade ago.
Eli Lilly and Co.
Articles
Lilly posts lackluster profit but boosts full-year forecast
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Alzheimer’s trials offer little certainty for investors, patients
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
Study shows Lilly’s Alzheimer’s drug has small but lasting benefit
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Lilly partner Immunocore raises record $320 million
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
PROXY CORNER: Eli Lilly and Co.
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Clot risk in Lilly lung-cancer drug raises FDA concerns
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
Resurgence of Eli Lilly is touching all corners of region
Central Indiana's economy is diverse, but Lilly is such a behemoth that its ups and downs reverberate statewide.
British court ruling backs patent protecting Lilly’s Alimta
Eli Lilly and Co. received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug.
Lilly facing first trials over Cymbalta withdrawal symptoms
Eli Lilly and Co. has been ordered to face claims it misled consumers about “brain zaps” and other withdrawal side effects tied to its antidepressant Cymbalta in the first cases slated to be heard by juries.
Lilly drug regimen costing $9,200 a month scores zero in study
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
Lilly buoyed by string of positive results from drug trials
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Startup aims to upend diabetes care with matchstick-size implant
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Eli Lilly says it has ‘no intention’ to spin off animal health unit
Eli Lilly stock rose 5.4 percent per share on Tuesday, its biggest daily increase since March 2009, after Elanco President Jeffrey Simmons was asked if Lilly might one day shed the unit in an initial public offering.
Lilly to launch Lantus biosimilar in Europe in third quarter
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
Great Indy Innovations
Central Indiana has been the birthplace of groundbreaking innovation felt nationwide–even worldwide.
Indy’s Golden Age in 1920s shows way forward
In the 1920s, Indianapolis was one of the most innovative cities in the nation. But after “the dark tragedy of the roaring twenties,” Indianapolis lost its edginess for decades and only recently has begun to regain it.
Pace-setting firms share advice on diving into change, accelerating innovation
IBJ picked the brains of Indianapolis-area firms and organizations known for liquid thinking to discover how they open the spigot on innovation.
Lilly to market euro bonds as low rates lure U.S. firms
The drugmaker plans to sell 2.1 billion euros ($2.3 billion) of securities in three parts, according to a person familiar with the matter who asked not to be identified.
Lilly pledges $60M to German firm to form research partnership
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.